Loading
A phase 2 trial in pancreatic cancer, run by Fudan University, now recruiting.
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas is a phase 2, interventional study registered as NCT06914674 by Fudan University, with a registry enrolment figure of 30 participants, started 2025-03-20 and due to reach its primary completion in 2027-02-28. Interventions recorded: Tamoxifen 20 mg. Conditions listed: Pancreatic Neoplasms. Primary outcome: Progression-free survival (PFSn). Pancreatic eligibility wording from the registry: ", pancreatitis)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.